Please upgrade your browser.
Major Annoucement on Kidney Cancer Vaccine
Roswell Park Launches Landmark Immunotherapy Vaccine Trial [Read More]
The ability to stretch out the attack for a long-term, durable response suggests that the vaccine may be effective in preventing disease recurrence. The new NY-ESO-1 dendritic cell vaccine is expected to show great promise in patients with bladder, brain, breast, esophageal, gastrointestinal, hepatocellular, kidney, lung, melanoma, ovarian, prostate, sarcoma and uterine tumors.
|NeonCRM by Neon One|